PGNY

Progyny is a high-quality, cash-generative business hiding behind a scary-looking P/E. The 10-K confirms an asset-light benefits-management model: revenue is utilization-driven (Smart Cycle case rates plus a tiny ~1% PEPM population fee), which is why reported gross margin is only 23.6% — case rates pass through third-party fertility specialists, anesthesiology, lab and Progyny Rx medications. The balance sheet is pristine: $516M equity against just $226M total liabilities (0.44x), $552M current assets vs $202M current liabilities (~2.7x current ratio), and effectively no debt. Most importantly, FY2025 operating cash flow of $210M (+17.4%) dwarfs $58.5M net income and easily funds the $18.4M capex and $81.7M of buybacks that cut the share count 4.1% — on cash flow the ~$2.36B market cap is a high-single-digit FCF yield, far cheaper than the 44x headline P/E suggests.

The catch is the growth-versus-profit gap. Revenue has 2.6x'd since FY2021 ($501M→$1.29B), yet net income is essentially flat over four years ($65.8M→$58.5M), so net margin has compressed from ~13% to 4.5%. That is the legacy of years of mix shift toward lower-margin pharmacy and case-rate pass-through. The encouraging FY2025 signal is operating leverage finally re-asserting: gross profit grew +20.2% and operating income +26.4% against revenue of +10.4%, lifting operating margin to 6.6%. But revenue growth itself has decelerated sharply (from +38% in FY2023 to +7–10% the last two years), and the model's utilization dependence and client-renewal cycle (noted in the MD&A) make the top line inherently lumpy and concentration-sensitive.